34,900 Shares in Parabilis Medicines, Inc. $PBLS Purchased by WINTON GROUP Ltd

WINTON GROUP Ltd bought a new stake in shares of Parabilis Medicines, Inc. (NASDAQ:PBLS) in the 2nd quarter, Holdings Channel reports. The firm bought 34,900 shares of the company’s stock, valued at approximately $955,000.

A number of other hedge funds have also recently modified their holdings of the business. Persistent Asset Partners Ltd purchased a new stake in shares of Parabilis Medicines in the second quarter worth approximately $113,000. Alyeska Investment Group L.P. bought a new position in Parabilis Medicines in the 2nd quarter valued at $274,000. Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in Parabilis Medicines in the 2nd quarter valued at $526,000. Squarepoint Ops LLC bought a new position in Parabilis Medicines in the 2nd quarter valued at $1,327,000. Finally, ICONIQ Capital LLC purchased a new stake in Parabilis Medicines in the second quarter worth $9,580,000.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on PBLS. Leerink Partners began coverage on Parabilis Medicines in a research report on Monday, July 6th. They set an “outperform” rating and a $40.00 target price for the company. Zacks Research upgraded shares of Parabilis Medicines to a “hold” rating in a report on Tuesday, July 7th. Lifesci Capital raised shares of Parabilis Medicines to a “strong-buy” rating in a research note on Monday, July 6th. Bank of America assumed coverage on shares of Parabilis Medicines in a report on Monday, July 6th. They set a “buy” rating and a $45.00 price objective for the company. Finally, Weiss Ratings assumed coverage on shares of Parabilis Medicines in a research report on Friday, September 4th. They issued a “sell (d)” rating for the company. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $41.67.

Parabilis Medicines Stock Performance

Shares of NASDAQ:PBLS opened at $36.88 on Monday. The business has a 50 day moving average price of $35.13. Parabilis Medicines, Inc. has a 52-week low of $24.51 and a 52-week high of $41.49.

Parabilis Medicines (NASDAQ:PBLS) last issued its earnings results on Thursday, August 13th. The company reported ($2.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($2.16). The business had revenue of $0.15 million during the quarter. As a group, equities research analysts predict that Parabilis Medicines, Inc. will post -2.05 earnings per share for the current fiscal year.

Parabilis Medicines Company Profile

Parabilis Medicines Inc is a clinical-stage biopharmaceutical company built to develop transformative medicines addressing some of the most consequential, yet historically undruggable, protein targets driving human disease. Parabilis Medicines Inc is based in CAMBRIDGE, Mass.